![Page 1: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/1.jpg)
Introduction to Immunization/ Vaccination
Hafez Sumairi
1
![Page 2: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/2.jpg)
Learning Objectives
At the end of this lecture, the student should:
Define the terms used in basic immunology and vaccination
Describe the various forms of immunity
Know the distinction between passive and active immunization and their examples
Describe the various types of vaccines
Distinguish between artificial and natural means of immunization
Outline the properties of ideal vaccines
Know the applications and problems of artificial passive immunization
Know the applications and problems of artificial active immunization
Describe new technology and ideas contributing to future vaccines development and delivery
Know the modern approaches to immunization
2
![Page 3: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/3.jpg)
Definitions
Immunization (Vaccination) is the process whereby a person is made immune or resistant to an infectious disease, typically by the administration of a vaccine.(WHO)
Immunogenicity: The inherent ability of an antigen to induce an immune response.
A vaccine is a biological preparation that improves immunity to a particular disease. (WHO)
Vaccine adjuvant: substance that is added to a vaccine to its immunogenicity without having any specific antigenic effect in itself.
Herd immunity: This develops when a high proportion of the target population in the community has been immunized with live vaccines, usually 80% and more in order to prevent the spread of infectious diseases
3
![Page 4: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/4.jpg)
Milestones in immunization
3000BC Evidence of sniffing powdered small pox crust in Egypt
2000BC Sniffing of small pox crust in China
1500BC Turks introduce variolation
1700AD Introduction of variolation in England and later in the US
1780AD
Edward Jenner discovers small pox vaccine
4
![Page 5: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/5.jpg)
Introduction of variolation
The wife of the British Ambassador in Turkey, in March 1717 wrote, following the variolation of her son, to a friend in England: “The small pox, so fatal, so general amongst us, is entirely harmless here by the invention of ingrafting….I am patriot enough to bring this invention into fashion in England.
5
![Page 6: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/6.jpg)
Edward Jenner
6
Discovery of small pox vaccine
![Page 7: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/7.jpg)
7
![Page 8: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/8.jpg)
Edward JennerAmong patients awaiting small pox vaccination
8
![Page 9: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/9.jpg)
Modern era of the vaccine
1885 Rabies vaccine (Pasteur)
1909 Bacillus calmette-Guerin (BCG)
1920s Diphtheria and Tetanus
1934 Pertussis & Yellow fever
1940s Diphtheria-tetanus-pertussis
(DTP) combination introduced
1955 Salk polio
1960s Mumps, measles and rubella virus
Sabin polio
1985 Haemophilus
First recombinant vaccine (hepatitis B)
1990s Hepatitis and varicella
First polysaccharide conjugate vaccine
Today-
Glycoconjugate vaccines, rotavirus vaccine, human papilloma virus vaccine and herpes zoster vaccine
9
![Page 10: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/10.jpg)
Aims of Immunisation Programmes
To protect those at highest risk (selective immunisation strategy) or
To eradicate, eliminate or control disease (mass immunisation strategy)
Currently, it is estimated that vaccination saves the lives of 3 million children a year
Eradication
Infection (pathogen) has been removed worldwide e.g. smallpox
Elimination
Disease has disappeared from one area but remains elsewhere e.g. polio, measles
Control
Disease no longer constitutes a significant public health problem e.g. neo-natal tetanus
10
![Page 11: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/11.jpg)
11
Pre- & post-vaccine incidence of common preventable diseases
![Page 12: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/12.jpg)
Different modes of acquiring immunity
Immunity
Natural resistance
Acquired
Passive
Artificial
Natural
Active
Natural
Artificial
12
![Page 13: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/13.jpg)
Passive Immunity
13
Passive Immunity
Natural resistance
Colostral transfer of IgA
Placental transfer of IgG
Artificial
Antibodies or immunoglobulins
Immune cells
![Page 14: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/14.jpg)
Passive Immunization
Disease Antibody
source
Indication
Diphtheria, tetanus Human, horse Prophylaxis, therapy
Vericella zoster Human Immunodeficiencies
Gas gangrene, botulism,
snake bite, scorpion sting
Horse Post-exposure
Rabies, Human Post-exposure
Hypogamma-globulinemia Human Post-exposure
14
![Page 15: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/15.jpg)
Advantages and Disadvantages of Passive Immunization
Advantages
• Immediate protection
Disadvantages
• No long term protection
• Serum sickness
• Risk of hepatitis and Aids
• Graft vs. host disease (cell graft only)
15
![Page 16: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/16.jpg)
16
![Page 17: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/17.jpg)
Active Immunity
17
Active Immunity
NaturalExposure to sub-
clinical infections
Artificial
Attenuated organisms
Killed organisms
Sub-cellular fragments
Toxins
Others
![Page 18: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/18.jpg)
Live Attenuated Vaccines
Polio
Measles, mumps & rubella
Varicella zoster children with no history of chicken pox
Hepatitis A
not required in SC
Yellow fever
Military and travelers
Tuberculosis
18
![Page 19: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/19.jpg)
Live Attenuated Vaccines
19
![Page 20: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/20.jpg)
Derivation of Sabin type 3 poliovirus vaccine
20
![Page 21: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/21.jpg)
Live Attenuated Vaccines
21
![Page 22: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/22.jpg)
New vaccine strategies: genetic reassortmentapproaches
22
![Page 23: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/23.jpg)
Advantages of attenuated vaccines
1. They activate all phases of immune system.
2. They raise an immune response to all protective antigens.
3. They offer more durable immunity and are more cross-reactive.
4. They cost less to produce
5. They give quick immunity in majority of vaccinees
6. In many cases (e.g. polio and adenovirus vaccines), administration is easy
7. These vaccines are easily transported in the field
8. They can lead to elimination of wild type virus from the community
23
![Page 24: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/24.jpg)
Disadvantages of Attenuated vaccine
1. Mutation.
2. Spread to contacts of the vaccinee who have not consented to be vaccinated (This could also be an advantage in communities where vaccination is not 100%)
3. Spread of the vaccine virus that is not standardized and may be mutated
4. Sometimes there is poor "take" in tropics
5. Live viruses are a problem in immunodeficiency disease patients
24
![Page 25: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/25.jpg)
Inactivated vaccines
•Virions inactivated by chemical procedures (e.g. formalin, β-propriolactone, nonionic detergents)
•Infectivity is eliminated but antigenicityis not compromised
25
![Page 26: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/26.jpg)
Killed Whole-Organism Vaccines
Polio
Influenza Elderly and at risk
Rabiespost exposure
Q feverPopulation at risk
Typhoid, cholera, plagueepidemics and travelers
PertussisReplaced by the acellular vaccine
26
![Page 27: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/27.jpg)
Microbial Fragment Vaccines
Bordetella pertussis
virulence factor protein
Haemophilus influenzae B
Protein conjugated polysaccharide
Streptococcus pneumoniae
Polysaccharide mixture
Neisseria meningitidis
Polysaccharide
Clostridium tetani (tetanus)
inactivated toxin (toxoid)
Corynebacterium diphtheriae
inactivated toxin (toxoid)
Vibrio cholerae
toxin subunits
Hepatitis B virus
Cloned in yeast
27
![Page 28: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/28.jpg)
Modification of Toxin to ToxoidModification of Toxin to Toxoid
28
toxin moiety antigenic determinants
chemical
modification
Toxin Toxoid
![Page 29: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/29.jpg)
29
![Page 30: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/30.jpg)
Inactivated vaccine
Advantages of inactivated vaccine
1. They give sufficient humoral immunity if boosters given
2. There is no mutation or reversion (This is a big advantage)
3. They can be used with immuno-deficient patients
4. Sometimes they perform better in tropical areas
Disadvantages of inactivated vaccines
1. Some vaccinees do not raise immunity
2. Boosters tend to be needed
3. There us little mucosal / local immunity (IgA)
4. Higher cost
5. In the case of polio, there is a shortage of monkeys
6. Failures of smallpox virus in inactivation
30
![Page 31: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/31.jpg)
31
![Page 32: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/32.jpg)
Recommended Childhood Immunization Schedule
32
![Page 33: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/33.jpg)
Future Vaccines (New Methods Of Vaccine Production)
1. Anti-Idiotype Vaccine
2. Immuno-dominant peptide (Synthetic peptides)
3. Recombinant vector vaccines
4. DNA
5. Others
33
![Page 34: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/34.jpg)
Anti-Idiotype Vaccine
34
![Page 35: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/35.jpg)
35
![Page 36: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/36.jpg)
36
![Page 37: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/37.jpg)
Recombinant vector vaccines
• Cloning of a gene into another virus
• Vaccinia (the smallpox vaccine virus) is a good candidate since it has been widely used in the human population with no ill effects.
37
![Page 38: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/38.jpg)
Conjugate or Multivalent Vaccines Can Improve Immunogenicity and Outcome
A conjugate vaccine protects against Haemophilus influenzaetype b (Hib)
38
![Page 39: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/39.jpg)
Multivalent subunit vaccines
39
![Page 40: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/40.jpg)
DNA vaccines The Third Vaccine Revolution
These vaccines are based on the deliberate introduction of a DNA plasmid into the vaccinee.
40
![Page 41: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/41.jpg)
Advantages of DNA vaccines
1. Production : Simpler and cheap –Plasmids-2. Stability : Does not require cold chain
3. Infectivity : No risk of infection
4. Flexibility : Fusion of multiple epitopes5. Versatility : Activates both cellular and humoral
immunity, long lasting immunity
6. DNA vaccines potentially have more widespreadapplications
7. Instead of injecting plasmid DNA into skeletal muscle, immune response can also induced by coating plasmid DNA onto gold beads and propel the beads into the skin by using a gene gun
41
![Page 42: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/42.jpg)
The Helios GENE GUN from BIORAD, USA
42
![Page 43: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/43.jpg)
Disadvantages (Possible Problems)
1. Potential integration of plasmid into host genome leading to insertional mutagenesis
2. Induction of autoimmune responses (e.g. pathogenic anti-DNA antibodies)
3. Induction of immunologic tolerance (e.g. where the expression of the antigen in the host may lead to specific non-responsiveness to that antigen)
43
![Page 44: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/44.jpg)
Disease targets for which DNA vaccines have been tested in animals
Viruses• Avian influenza, bovine herpes, bovine viral diarrhea virus, dengue fever,
encephalitis, feline immunodeficiency virus, hepatitis B, hepatitis C, human cytomegalovirus, herpes simplex virus, human immunodeficiency virus I, influenza, lymphocytic choriomeningitis virus, measles, papilloma, rabies, respiratory syncitial virus, simian immunodeficiency virus, simian virus 40.
Bacteria• Borrelia burgdorferi (Lyme disease), Moraxella bovis, Mycobacterium
tuberculosis, Mycoplasma, Ricketsia, Salmonella, tetanus toxin.
Parasites• Cryptosporidium parvum, Leishmania, Plasmodium falciparum (malaria),
Schistosoma.
Cancer-associated antigens • Carcinoembryonic antigen (CEA), melanoma-associated antigen, the MHC
molecule HLA-B7.
• There have been more than 42 Phase I/II clinical trials involving DNA Vaccines.
44
![Page 45: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/45.jpg)
New vaccine strategies: reverse genetic approaches
45
![Page 46: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/46.jpg)
46
![Page 47: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/47.jpg)
Adverse Events Occurring Within 48 Hours DTP of Vaccination
Event Local
redness, swelling, pain
Systemic: Mild/moderate fever, drowsiness, fretfulness
vomiting anorexia
Systemic: more serious persistent crying, fever collapse, convulsions acute encephalopathy permanent neurological deficit
Frequency
• 1 in 2-3 doses
• 1 in 2-3 doses
• 1 in 5-15 doses
• 1 in 100-300 doses
• 1 in 1750 doses
• 1 in 100,000 doses
• 1 in 300,000 doses
47
![Page 48: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/48.jpg)
Vaccine constituents
Active material(s): Antigens or molecules that react with specific receptors on T and B cells and activate these cells to induce antigen-specific T and B immune responses.
Inactive materials
Adjuvants (aluminium salts, mono-phosphoryl lipid A or MPL, etc) enhance immune responses of vaccine antigens
Preservatives (phenoxyethanol, formaldehyde, thiomersal / thimerosal, or antibiotics) prevent bacterial growth especially in multi-dose vaccines
Stabilizers (proteins or other organic compounds) extend the shelf-life of the vaccine
Salts and acidic solutions (sodium hydroxide, sodium chloride, sodium borate and acetic acid) maintain pH
Solvents such as calcium carbonate, xanthan gum and sterile water
Diluents for reconstituting lyophilised or freeze-dried vaccines
48
![Page 49: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/49.jpg)
Vaccine adjuvant
Adjuvant type Human use Experimental only
Salts:
Aluminum hydroxide,
aluminum phosphate-calcium
phosphate
Yes
Yes Slow release of antigen, TLR
interaction and cytokine induction
Beryllium hydroxide No
Synthetic particles:Liposomes, ISCOMs,
polylactates
No
NoSlow release of antigen
Polynucleotides:CpG and others No*
TLR interaction and cytokine
induction
Bacterial products:B. pertussis
YesTLR interaction and cytokine
inductionM. bovis (BCG and others) No
Mineral oils No Antigen depot
Cytokines:IL-1, IL-2, IL12, IFN-γ, etc.
No*Activation and differentiation of T-
and B cells and APC49
![Page 50: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/50.jpg)
Characteristics of an ideal vaccine
1. Immunogenic, provoking a good immune response; but not pathogenic
2. Providing long-lasting immunity
3. Safe, with no or very rare adverse event following immunization (AEFIs)
4. Stable in field conditions and can be stored reasonably long without or with minimum cold chain requirements (heat stable)
5. Combined with several antigens producing immunity against a number of diseases
6. Effective after a single dose hence requires few immunizations to induce protection
7. Administered preferably by non-injectable routes (oral or through inhalation)
8. With affordable cost and accessible to all
50
![Page 51: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/51.jpg)
Characteristics of an ideal vaccine
9. Suitable for administration early and late in life (Effective in the old & very young)
10. Give life-long immunity
11. Broadly protective against all variants of organism
12. Prevent disease transmission
13. Rapidly induce immunity
14. Transmit maternal protection to the baby
51
![Page 52: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/52.jpg)
52
![Page 53: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/53.jpg)
Challenges in vaccine development
1. Adaptation of microbial agents to host immunityDevelopment of escape strategies by microbes:i. Emergence of new antigenic variants (e.g. Pneumo, flu,
Menb, malaria, HIV, tb…)ii. Complex interaction with host immune system (e.g.
immunomodulation)
2. Different types of virus may cause similar diseases
3. Antigenic drift and shift
4. Large animal reservoirs
5. Integration of viral DNA
6. Transmission from cell to cell via syncytia
7. Recombination and mutation of the vaccine virus in an attenuated vaccine
53
![Page 54: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/54.jpg)
Future vaccine development
•Improved vaccines for optimizing immunogenicity & safety1. New adjuvants used to optimize b cell
responses (level, quality, duration, memory) and generate appropriate t cell responses (help, effector, memory)
2. Immune system targeting formulations
3. New live vaccine vectors (non-replicating)
54
![Page 55: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/55.jpg)
55
![Page 56: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/56.jpg)
56
![Page 57: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/57.jpg)
Viral Vaccines
57
![Page 58: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/58.jpg)
Bacterial Vaccines
58
![Page 59: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/59.jpg)
Target Fungal Vaccines
59
![Page 60: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/60.jpg)
Target Parasitic Disease
• Malaria
• Trypanosomiasis
• Leishmaniasis
• Toxoplasmosis
60
![Page 61: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/61.jpg)
Selective Vaccination
Vaccine given specifically to those at increased risk of disease:
• High risk groups
e.g. Pneumococcal vaccine
• Occupational risk
e.g. Hepatitis B, influenza
• Travellers
e.g. Yellow fever, rabies, meningitis
• Outbreak control
e.g. Hepatitis A. vaccine, measles
61
![Page 62: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/62.jpg)
More Possibilities
Therapeutic vaccines: Identification of specific tumor
antigens provide immune targets for which immunogenic
vaccines may conceivably be designed. Examples:
Leukemia
Breast cancer
Melanoma
Prostate cancer
Colon cancer
•Vaccines against autoimmune diseases
62
![Page 63: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/63.jpg)
Similarities between Vaccines and other Drug
Vaccines are also medicines
Potential for adverse effects
Multiple ingredients
Potential for interaction with disease and other medicines
Also need to comply with standards of safety, efficacy and quality
63
![Page 64: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/64.jpg)
Mass Vaccination (Herd immunity)
Objective: Make hosts resistant to infection without
having to experience disease
64
![Page 65: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/65.jpg)
Impact of Mass Vaccination Programmes
Reduce size of susceptible population
Reduce number of cases
•Reduce risk of infection in population
•Reduce contact of susceptible to cases
•Lengthening of epidemic cycle ->
honeymoon phase
• Increase in mean age of infection
65
![Page 66: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/66.jpg)
No Mass Vaccination
66
Each host in contact with infected host becomes infected
(with a certain probability)
![Page 67: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/67.jpg)
Mass Vaccination
67
Outbreak attenuated (or averted) by lack of susceptible hosts
![Page 68: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/68.jpg)
Steps on Vaccine Development1
• Recognize the disease as a distinct entity
• Identify etiologic agent
• Grow agent in laboratory
• Establish in animal model for disease
• Identify an immunologic correlate for immunity to the disease- usually serum
antibody
• Inactivate or attenuate the agent in the laboratory- or choose antigens
• Prepare candidate vaccine following GOOD manufacturing Procedures
• Evaluate candidate vaccine(s) for ability to protect animals
68
![Page 69: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/69.jpg)
Steps on Vaccine Development2
• Prepare protocol(s) for human studies
• Apply to MCC for investigational New drug (IND) approval
• Phase I human trials- Safety and immugenicity, dose response
• Phase II trials- Safety and immugenicity
• Phase III trials- Efficacy
69
![Page 70: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/70.jpg)
Steps on Vaccine Development3
• Submit Product Licensure Application MCC approval
• Advisory Committees review and make recommendations
• Marketing Post- Licensure Surveillance for safety and effectiveness
(Phase IV)
• Long and Complicated process
Usually takes 10-15 years
Many vaccine candidates fail for every success
Costs: $ 100- $ 700 million per successful vaccine
70
![Page 71: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/71.jpg)
Vaccine Evaluation
Pre-licensingRandomised, Blinded,
Controlled Clinical Trials
Vaccine efficacy:Protective Effect under Idealised
Conditions
RCT: controlled experiments, simple interpretation
Post-licensingObservational Studies
Vaccine effectiveness:Protective Effect under
Ordinary Conditions of a public health programme
Prone to bias, more complex interpretation
71
![Page 72: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/72.jpg)
The eradication of smallpox due to several reasons
1. There is no animal reservoir for variola
2. Lifelong immunity, although this may not be the case with people immunized using the vaccine strain
3. Subclinical cases are rare
4. Infectivity does not precede overt symptoms, that is there is no prodromal phase
5. There is only one Variola serotype
6. The vaccine is very effective
7. There has been a major commitment by the World Health Organization and governments to smallpox eradication.
72
![Page 73: Introduction to immunization (vaccination) 2016 2017](https://reader031.vdocuments.us/reader031/viewer/2022021503/5883692c1a28ab536b8b5d3f/html5/thumbnails/73.jpg)
Thank you
?73